Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2022 | CD229 as a potential therapeutic target for multiple myeloma

Carlos Fernández De Larrea • 10 Jun 2022
EHA 2022
Multiple Myeloma Smoldering Myeloma

Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, highlights the potential of CD229 as a therapeutic target in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Carlos Fernández De Larrea

Novel therapeutic strategies in multiple myeloma
Carlos Fernández De Larrea et al. • 15 Apr 2023
Safety & efficacy cesnicabtagene autoleucel (ARI0002H) in R/R multiple myeloma 5:35
Safety & efficacy cesnicabtagene autoleucel (ARI0002H) in R/R multiple myeloma
Carlos Fernández De Larrea • 11 Jun 2022
Managing progression after BCMA-targeted therapy in R/R multiple myeloma 1:02
Managing progression after BCMA-targeted therapy in R/R multiple myeloma
Carlos Fernández De Larrea • 10 Jun 2022
Safety and efficacy of cesnicabtagene autoleucel (ARI0002h) for R/R MM 1:22
Safety and efficacy of cesnicabtagene autoleucel (ARI0002h) for R/R MM
Carlos Fernández De Larrea • 10 Jun 2022

Related Videos

The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma 4:45
The iMMunoPET trial: 89Zr-DFO-daratumumab for CD38-targeted imaging of multiple myeloma
Ola Landgren • 6 Dec 2025
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry 1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3 2:33
The hottest myeloma abstracts from ASH 2025: in vivo CAR-T and MajesTEC-3
Faith Davies • 7 Dec 2025
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL 2:30
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals